Inhibitor

(redirected from DPP-4 inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Legal.

inhibitor

[in′hib·əd·ər]
(aerospace engineering)
A substance bonded, taped, or dip-dried onto a solid propellant to restrict the burning surface and to give direction to the burning process.
(chemistry)
A substance which is capable of stopping or retarding a chemical reaction; to be technically useful, it must be effective in low concentration.

Inhibitor

 

a circuit having m + n inputs and a single output, at which a signal can appear only when there are no signals on the m inputs (inhibiting). The other n inputs (principal) form one of the two logic connections, “AND” or “OR.” Inhibitors are used extensively in computers. They are very often understood to be a circuit having a single principal input and a single inhibiting input. A signal appears at the output of such a circuit when a signal is present on the principal input but there is none on the inhibiting input. Such an inhibitor is called an anticoincidence gate; its conventional representation is given in Figure 1.

Figure 1. Block diagram of an anticoincidence gate (inhibitor) with m — 1 and n 1:(A) principal input, (Q) inhibiting input, (Ga) anticoincidence gate

inhibitor

A substance added to paint to retard drying, skinning, mildew growth, etc. Also see corrosion inhibitor, inhibiting pigment, drying inhibitor.
References in periodicals archive ?
AstraZeneca supported the CREST study and the sulfonylureas versus DPP-4 inhibitor comparison study.
However, these well conducted studies bring up some consideration about the use of DPP-4 inhibitors in diabetic patients with RA.
Other findings included an increased risk of acute pancreatitis among those who had recently started treatment with a DPP-4 inhibitor and in those who had recently started treatment with several other antihyperglycemic drugs, including sulfonylureas and insulin.
Empagliflozin is an investigational SGLT2 inhibitor being studied for the treatment of type 2 diabetes, and linagliptin, a DPP-4 inhibitor, is approved for the treatment of type 2 diabetes along with diet and exercise.
Linagliptin belongs to the class of DPP-4 inhibitors and is being developed as an oral once-daily tablet.
She presented a retrospective study examining treatment utilization patterns among 134,696 commercially insured type 2 diabetes patients placed on a GLP-1 agonist, 202,269 given a DPP-4 inhibitor, and 1,014,630 on other antidiabetic agents.
As highlighted within the NICE guideline, the latest data on the DPP-4 inhibitor sitagliptin has shown that treatment with sitagliptin was associated with fewer hypoglycaemic events compared to treatment with metformin and glipizide, a sulphonylurea, 5% versus 32% respectively.
And, the combination of a DPP-4 inhibitor and a TZD robustly drops hemoglobin Al, and also makes physiologic sense since they work by two different mechanisms, added Dr.
Sitagliptin is part of a new class of oral treatments known as dipeptidyl peptidase-4 (DPP-4) inhibitors that enhance the body's own ability to lower blood sugar (glucose) when it is elevated, became the first approved DPP-4 inhibitor in the world when it received regulatory approval in Mexico in August.
In addition, the synergy demonstrated with a DPP-4 inhibitor provides the mechanistic rationale to consider future combination therapies.
Tikkinen restricted his comments to the meta-analysis of the DPP-4 inhibitor trials; the GLP-1 agonist meta-analysis will be presented at a later date.
Sitagliptin, part of a new class of oral treatments known as dipeptidyl peptidase-4 (DPP-4) inhibitors that enhance the body's own ability to lower blood sugar (glucose) when it is elevated, became the first approved DPP-4 inhibitor in the world when it received regulatory approval in Mexico in August.